Vitiligo affects nearly 1% of the entire global population. The World Vitiligo Foundation reveals that approximately 70 million have developed the condition, out of which around 20-35% are children. The prevalence rate ranges from 1-2% worldwide, with no boundaries of gender, race, or ethnicity.
Major companies involved in the Vitiligo drugs market include Pfizer & Co., Inc., AbbVie Inc., Incyte Corporation, Reistone Biopharma Company Limited and Vyne Therapeutics Inc., among others.
Leading drugs currently under pipeline include Upadacitinib, Povorcitinib and Afamelanotide, among others.
The drug pipeline for vitiligo is impacted by the increased inclination of regulatory authorities like the United States FDA and EMA to offer breakthrough designations and fast-track approvals to various drugs.
The Vitiligo Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into vitiligo therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for vitiligo. The vitiligo report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The vitiligo pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with vitiligo treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to vitiligo.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Vitiligo is an autoimmune skin disorder characterized by loss of pigment from skin patches, leading to pale white spots. The condition occurs when the body’s immune system starts destroying melanocytes (skin cells that provide pigment or color). It can be categorized into several types such as generalized vitiligo (also known as nonsegmental vitiligo), segmental vitiligo, mucosal as well as focal vitiligo.
Vitiligo can affect individuals across all ages, races and genders. However, the condition is slightly more visible in people with a deeper skin tone. The treatment for vitiligo is not necessary as the condition doesn’t cause any pain or harm to the body. However, this condition can hamper the emotional well-being of an individual. Therefore, treatments like medications, light therapy, depigmentation therapy, and surgery are available. In medications, corticosteroids, topical Janus kinase inhibitors (ruxolitinib) and calcineurin inhibitors are amongst the common drug classes.
In June 2024, the United States FDA approved the first JAK inhibitor called Ruxolitinib (Opzelura). It is applied directly to the affected areas and has fewer side effects in comparison to the oral medicines available.
Across 11 studies covering over 470 million person-years, the incidence of vitiligo was found to be 1.59 cases per 10,000 person-years. Most of these studies were based in North America and Europe. Additionally, 112 studies reported on vitiligo's global prevalence, which was estimated at 0.40%. The highest prevalence was observed in West Asia, while East Asia reported the lowest.
This section of the report covers the analysis of vitiligo drug candidates based on several segmentations, including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Drug Class
EMR’s vitiligo report assessment covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s vitiligo report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. EMR analysis shows phase II covers a major share of the total clinical trials conducted. The vitiligo drug pipeline includes a total of 88 drugs across various development stages. Phase 2 holds the largest share, accounting for around 44% of the pipeline, followed by Phase 3 at 28%. Phase 1 makes up about 13%, while Phase 4 represents 10%. Early Phase 1 has the smallest share, contributing just 5%. This reflects a strong focus on mid-stage clinical research for vitiligo treatments.
The drug class categories covered under vitiligo pipeline analysis include corticosteroids, calcineurin inhibitors, psoralens, and UVA (PUVA), immunomodulators , Janus kinase (JAK) inhibitors, monoclonal antibodies, and melanocyte-stimulating agents, among others. Corticosteroids like Clobetasol Propionate and Betamethasone Valerate are used to reduce inflammation and stimulate pigment production. Calcineurin inhibitors are specifically designed for sensitive areas such as the face and groin. Janus kinase (JAK) inhibitors are a relatively newer class of drugs that inhibit the pathway of immune response.
The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials.
The EMR vitiligo drug pipeline report covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in vitiligo clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for vitiligo. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of vitiligo drug candidates.
This drug is part of Phase 2b multicenter, randomized, double-blind, placebo-controlled study for nonsegmental vitiligo. Developed by AbbVie Inc., Upadacitinib showed positive results for over 70% of the participants. At week 52, the cohort which was receiving an 11mg dosage showed a 63% improvement in facial vitiligo (F-VASI)
It is an oral small-molecule JAK1 inhibitor, investigated for its efficacy and safety on adult patients with extensive nonsegmental vitiligo. Povorcitinib is currently in a Phase 2b randomized, double-blind, placebo-controlled, dose-ranging clinical trial. It has been well tolerated in patients.
Afamelanotide (SCENESSE®, Clinuvel Pharmaceuticals) is a potential drug alternative for vitiligo. It is an alpha-melanocyte-stimulating hormone (αMSH) analogue and works by regulating the production of eumelanin (a form of melanin). The drug is being investigated as a monotherapy in CUV104, a new clinical study.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Vitiligo Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for vitiligo. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within vitiligo pipeline insights.
Global Vitiligo Treatment Market
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share